Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC

Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited to its very broad spectrum of inhibition of angioge...

Descripción completa

Detalles Bibliográficos
Autores principales: Granito, Alessandro, Marinelli, Sara, Forgione, Antonella, Renzulli, Matteo, Benevento, Francesca, Piscaglia, Fabio, Tovoli, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165211/
https://www.ncbi.nlm.nih.gov/pubmed/34079777
http://dx.doi.org/10.2147/JHC.S251729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165211/
https://www.ncbi.nlm.nih.gov/pubmed/34079777
http://dx.doi.org/10.2147/JHC.S251729

Ejemplares similares